Please Wait
Applying Filters...
menu
    • menu
    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-24

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-17

    Virtual Booth

    Contact Supplier

    Menu

    Stenoparib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Allarity's Ph2 Stenoparib Lung Cancer Trial Fully Funded By VA
    Allarity's Ph2 Stenoparib Lung Cancer Trial Fully Funded By VA

    06 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/06/3038114/0/en/Allarity-Therapeutics-Announces-Phase-2-Trial-of-Stenoparib-in-Combination-with-Temozolomide-for-Recurrent-Small-Cell-Lung-Cancer-Fully-Funded-by-the-US-Veterans-Administration.html

    GLOBENEWSWIRE
    06 Mar 2025
    Share Share
    Allarity to Start Phase 2 for Stenoparib in Ovarian Cancer
    Allarity to Start Phase 2 for Stenoparib in Ovarian Cancer

    24 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/24/3031065/0/en/Allarity-Therapeutics-to-Begin-Enrollment-for-New-Phase-2-Protocol-to-Advance-Stenoparib-Toward-FDA-Approval-in-Advanced-Ovarian-Cancer-Patients.html

    GLOBENEWSWIRE
    24 Feb 2025
    Share Share
    Allarity Adds Leaders To Advance Stenoparib PARP Program
    Allarity Adds Leaders To Advance Stenoparib PARP Program

    03 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/03/2957638/0/en/Allarity-Therapeutics-Strengthens-Leadership-with-Key-Appointments-to-Accelerate-Stenoparib-PARP-Inhibitor-Program.html

    GLOBENEWSWIRE
    03 Oct 2024
    Share Share
    Allarity Stenoparib Shows Extended Benefit in Advanced Ovarian Cancer
    Allarity Stenoparib Shows Extended Benefit in Advanced Ovarian Cancer

    25 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/25/2903722/0/en/Allarity-Therapeutics-Dual-PARP-Tankyrase-Inhibitor-Stenoparib-Continues-to-Show-Extended-Clinical-Benefit-in-Advanced-Ovarian-Cancer.html

    GLOBENEWSWIRE
    25 Jun 2024
    Share Share
    Allarity Reports Q1 Results, Clinical Benefits, NASDAQ Compliance
    Allarity Reports Q1 Results, Clinical Benefits, NASDAQ Compliance

    14 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/14/2881841/0/en/Allarity-Therapeutics-Reports-First-Quarter-Financial-Results-and-Highlights-including-Clear-Clinical-Benefits-from-Phase-2-Trial-NASDAQ-Compliance-and-Significant-Improvement-in-C.html

    GLOBENEWSWIRE
    14 May 2024
    Share Share
    Allarity Stenoparib Shows Clear Clinical Benefit and Achieves Milestone
    Allarity Stenoparib Shows Clear Clinical Benefit and Achieves Milestone

    02 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/02/2874113/0/en/Allarity-Therapeutics-Stenoparib-Shows-Clear-Clinical-Benefit-and-Achieves-Significant-Milestone-with-Early-Conclusion-of-Phase-2-Trial-in-Advanced-Ovarian-Cancer.html

    GLOBENEWSWIRE
    02 May 2024
    Share Share